Cargando…
Folate Receptor-Beta Has Limited Value for Fluorescent Imaging in Ovarian, Breast and Colorectal Cancer
AIMS: Tumor-specific targeted imaging is rapidly evolving in cancer diagnosis. The folate receptor alpha (FR-α) has already been identified as a suitable target for cancer therapy and imaging. FR-α is present on ~40% of human cancers. FR-β is known to be expressed on several hematologic malignancies...
Autores principales: | , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Public Library of Science
2015
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4527727/ https://www.ncbi.nlm.nih.gov/pubmed/26248049 http://dx.doi.org/10.1371/journal.pone.0135012 |
_version_ | 1782384604806643712 |
---|---|
author | de Boer, Esther Crane, Lucia M. A. van Oosten, Marleen van der Vegt, Bert van der Sluis, Tineke Kooijman, Paulien Low, Philip S. van der Zee, Ate G. J. Arts, Henriette J. G. van Dam, Gooitzen M. Bart, Joost |
author_facet | de Boer, Esther Crane, Lucia M. A. van Oosten, Marleen van der Vegt, Bert van der Sluis, Tineke Kooijman, Paulien Low, Philip S. van der Zee, Ate G. J. Arts, Henriette J. G. van Dam, Gooitzen M. Bart, Joost |
author_sort | de Boer, Esther |
collection | PubMed |
description | AIMS: Tumor-specific targeted imaging is rapidly evolving in cancer diagnosis. The folate receptor alpha (FR-α) has already been identified as a suitable target for cancer therapy and imaging. FR-α is present on ~40% of human cancers. FR-β is known to be expressed on several hematologic malignancies and on activated macrophages, but little is known about FR-β expression in solid tumors. Additional or simultaneous expression of FR-β could help extend the indications for folate-based drugs and imaging agents. In this study, the expression pattern of FR-β is evaluated in ovarian, breast and colorectal cancer. METHODS: FR-β expression was analyzed by semi-quantitative scoring of immunohistochemical staining on tissue microarrays (TMAs) of 339 ovarian cancer patients, 418 breast cancer patients, on 20 slides of colorectal cancer samples and on 25 samples of diverticulitis. RESULTS: FR-β expression was seen in 21% of ovarian cancer samples, 9% of breast cancer samples, and 55% of colorectal cancer samples. Expression was weak or moderate. Of the diverticulitis samples, 80% were positive for FR-β expression in macrophages. FR-β status neither correlated to known disease-related variables, nor showed association with overall survival and progression free survival in ovarian and breast cancer. In breast cancer, negative axillary status was significantly correlated to FR-β expression (p=0.022). CONCLUSIONS: FR-β expression was low or absent in the majority of ovarian, breast and colorectal tumor samples. From the present study we conclude that the low FR-β expression in ovarian and breast tumor tissue indicates limited practical use of this receptor in diagnostic imaging and therapeutic purposes. Due to weak expression, FR-β is not regarded as a suitable target in colorectal cancer. |
format | Online Article Text |
id | pubmed-4527727 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2015 |
publisher | Public Library of Science |
record_format | MEDLINE/PubMed |
spelling | pubmed-45277272015-08-12 Folate Receptor-Beta Has Limited Value for Fluorescent Imaging in Ovarian, Breast and Colorectal Cancer de Boer, Esther Crane, Lucia M. A. van Oosten, Marleen van der Vegt, Bert van der Sluis, Tineke Kooijman, Paulien Low, Philip S. van der Zee, Ate G. J. Arts, Henriette J. G. van Dam, Gooitzen M. Bart, Joost PLoS One Research Article AIMS: Tumor-specific targeted imaging is rapidly evolving in cancer diagnosis. The folate receptor alpha (FR-α) has already been identified as a suitable target for cancer therapy and imaging. FR-α is present on ~40% of human cancers. FR-β is known to be expressed on several hematologic malignancies and on activated macrophages, but little is known about FR-β expression in solid tumors. Additional or simultaneous expression of FR-β could help extend the indications for folate-based drugs and imaging agents. In this study, the expression pattern of FR-β is evaluated in ovarian, breast and colorectal cancer. METHODS: FR-β expression was analyzed by semi-quantitative scoring of immunohistochemical staining on tissue microarrays (TMAs) of 339 ovarian cancer patients, 418 breast cancer patients, on 20 slides of colorectal cancer samples and on 25 samples of diverticulitis. RESULTS: FR-β expression was seen in 21% of ovarian cancer samples, 9% of breast cancer samples, and 55% of colorectal cancer samples. Expression was weak or moderate. Of the diverticulitis samples, 80% were positive for FR-β expression in macrophages. FR-β status neither correlated to known disease-related variables, nor showed association with overall survival and progression free survival in ovarian and breast cancer. In breast cancer, negative axillary status was significantly correlated to FR-β expression (p=0.022). CONCLUSIONS: FR-β expression was low or absent in the majority of ovarian, breast and colorectal tumor samples. From the present study we conclude that the low FR-β expression in ovarian and breast tumor tissue indicates limited practical use of this receptor in diagnostic imaging and therapeutic purposes. Due to weak expression, FR-β is not regarded as a suitable target in colorectal cancer. Public Library of Science 2015-08-06 /pmc/articles/PMC4527727/ /pubmed/26248049 http://dx.doi.org/10.1371/journal.pone.0135012 Text en © 2015 de Boer et al http://creativecommons.org/licenses/by/4.0/ This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are properly credited. |
spellingShingle | Research Article de Boer, Esther Crane, Lucia M. A. van Oosten, Marleen van der Vegt, Bert van der Sluis, Tineke Kooijman, Paulien Low, Philip S. van der Zee, Ate G. J. Arts, Henriette J. G. van Dam, Gooitzen M. Bart, Joost Folate Receptor-Beta Has Limited Value for Fluorescent Imaging in Ovarian, Breast and Colorectal Cancer |
title | Folate Receptor-Beta Has Limited Value for Fluorescent Imaging in Ovarian, Breast and Colorectal Cancer |
title_full | Folate Receptor-Beta Has Limited Value for Fluorescent Imaging in Ovarian, Breast and Colorectal Cancer |
title_fullStr | Folate Receptor-Beta Has Limited Value for Fluorescent Imaging in Ovarian, Breast and Colorectal Cancer |
title_full_unstemmed | Folate Receptor-Beta Has Limited Value for Fluorescent Imaging in Ovarian, Breast and Colorectal Cancer |
title_short | Folate Receptor-Beta Has Limited Value for Fluorescent Imaging in Ovarian, Breast and Colorectal Cancer |
title_sort | folate receptor-beta has limited value for fluorescent imaging in ovarian, breast and colorectal cancer |
topic | Research Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4527727/ https://www.ncbi.nlm.nih.gov/pubmed/26248049 http://dx.doi.org/10.1371/journal.pone.0135012 |
work_keys_str_mv | AT deboeresther folatereceptorbetahaslimitedvalueforfluorescentimaginginovarianbreastandcolorectalcancer AT craneluciama folatereceptorbetahaslimitedvalueforfluorescentimaginginovarianbreastandcolorectalcancer AT vanoostenmarleen folatereceptorbetahaslimitedvalueforfluorescentimaginginovarianbreastandcolorectalcancer AT vandervegtbert folatereceptorbetahaslimitedvalueforfluorescentimaginginovarianbreastandcolorectalcancer AT vandersluistineke folatereceptorbetahaslimitedvalueforfluorescentimaginginovarianbreastandcolorectalcancer AT kooijmanpaulien folatereceptorbetahaslimitedvalueforfluorescentimaginginovarianbreastandcolorectalcancer AT lowphilips folatereceptorbetahaslimitedvalueforfluorescentimaginginovarianbreastandcolorectalcancer AT vanderzeeategj folatereceptorbetahaslimitedvalueforfluorescentimaginginovarianbreastandcolorectalcancer AT artshenriettejg folatereceptorbetahaslimitedvalueforfluorescentimaginginovarianbreastandcolorectalcancer AT vandamgooitzenm folatereceptorbetahaslimitedvalueforfluorescentimaginginovarianbreastandcolorectalcancer AT bartjoost folatereceptorbetahaslimitedvalueforfluorescentimaginginovarianbreastandcolorectalcancer |